At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Treprostinildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
In Brief
A Phase 2 clinical trial evaluating Treprostinil for Pulmonary Arterial Hypertension and 2 related conditions. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsUnited Therapeutics
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionJan 2011
Study CompletionApr 2011
TodayJul 2026
First PostedJun 25, 2008
Enrollment StartJul 1, 2008
Primary CompletionJan 1, 2011
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.0 years ago
Interventions
Treprostinildrug
For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated